Regeneron Pharmaceuticals, Inc.
REGENERON PHARMACEUTICALS INC (Form: 4, Received: 08/09/2017 16:05:50)
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Landry Robert E
2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS INC [ REGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
SVP Finance & CFO
(Last)          (First)          (Middle)

777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

8/7/2017
(Street)

TARRYTOWN, NY 10591
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   8/7/2017     M (1)    2000   A $272.7   9099   D    
Common Stock   8/7/2017     F (1)    1167   D $466.98   7932   D    
Common Stock   8/7/2017     F (1)    307   D $466.98   7625   D    
Common Stock   8/8/2017     S (1)    100   D $469.91   7525   D    
Common Stock   8/8/2017     S (1)    100   D $471.0   7425   D    
Common Stock   8/8/2017     S (1)    100   D $472.54   7325   D    
Common Stock   8/8/2017     S (1)    226   D $473.57   (2) 7099   D    
Common Stock                  83   I   By 401(k) Plan  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy)   $272.7   8/7/2017     M   (1)       2000      (3) 9/9/2023   Common Stock   2000   $0.0   64000   D    

Explanation of Responses:
(1)  Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2)  Represents volume-weighted average price of sales of 226 shares of Company stock on August 8, 2017 at prices ranging from $473.27 to $472.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2017 at each separate price.
(3)  The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Landry Robert E
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591


SVP Finance & CFO

Signatures
/s/**Robert E. Landry 8/9/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.